Quantcast

Latest Tapentadol Stories

2011-05-17 15:00:00

WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). In the study presented at the annual meeting of the American Urological Association, RAPAFLO(R) also significantly improved urinary symptoms as well as quality of life. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition characterized by persistent...

2011-04-22 07:23:00

TALLAHASSEE, Fla., April 22, 2011 /PRNewswire/ -- The Florida Society of Pain Management Providers (www.Flspmp.org) urges Government, Law Enforcement and the media to stop using false prescription drug data and statistics. The continued release of false and / or out of context information is solely intended to enflame the public. The misinformation that unfairly portrays Florida as ground zero in this issue has significant consequences for pain management patients and the physicians who...

2011-04-21 08:57:00

CAMBRIDGE, England, April 21, 2011 /PRNewswire/ -- - First-time-in-man Study Initiated Ahead of Schedule Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun. The trial is a randomised, placebo...

2011-04-14 07:31:00

SYDNEY, Australia and BEDMINSTER, N.J., April 14, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029. This patent covers a proprietary dosing algorithm for converting patients from intravenous opioid administration to orally administered MoxDuo IR, thereby more effectively and safely managing acute pain following surgery....

2011-04-04 07:01:00

NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced additional data that showed that overweight and obese patients treated with Contrave® (naltrexone sustained release (SR)/bupropion SR) maintained normal 24-hour circadian patterns over one year of treatment. These data were from the ambulatory blood pressure monitoring (ABPM) sub-study of the COR-II trial that also showed weight loss and improvements in...

2011-03-30 07:00:00

SHELTON, Conn., March 30, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the appointment of James B. Jones, M.D., Pharm.D., to the position of Chief Medical Officer. In this role, Dr. Jones will oversee the ongoing clinical development of Cara's lead drug candidate, CR845, a novel, peripherally-restricted kappa opioid agonist, which is currently in Phase 2 development for treatment of post-operative pain. "We are delighted to add someone of Jim's clinical background and drug...

2011-03-25 05:00:00

NATIONAL HARBOR, Md., March 25, 2011 /PRNewswire-USNewswire/ -- Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period. "Butrans is a new treatment for chronic pain that was...

2011-03-15 11:06:00

SAN FRANCISCO, March 15, 2011 /PRNewswire/ -- AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to investigate the safety and efficacy of NKTR-118 as a medicine to relieve opioid induced constipation, a common side effect of prescription opioids when used for chronic...

2011-03-11 12:29:00

TALLAHASSEE, Fla., March 11, 2011 /PRNewswire/ -- The Florida Society of Pain Management Providers (www.Flspmp.org) releases the latest facts on Oxycodone and Hydrocodone use in the United States. Until now these statistics were not readily available to the public or media. Oxycodone dispensed in U.S. 2009 by state (per 100,000 population) ------------------------------------------------------------------ Methodology: Sources: DEA 2009 ARCOS report, US Census and FDA....

2011-02-23 00:00:42

Company Successfully Completes Third Pivotal MoxDuo® Phase 3 Study Sydney, Australia and Bedminster, New Jersey (Vocus/PRWEB) February 21, 2011 QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo. Designed to evaluate the analgesic efficacy and...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related